The evidence of the effectiveness of the oral immunostimulant OM-89 is promising. Although sometimes statistically significant, pooled findings for the other interventions should be considered tentative until corroborated by more research. Large head-to-head trials should be performed to optimally inform clinical decision making.

No abstract

was aimed at discerning the relationships between the FVC variables, gender and age. RESULTSThere was a linear increase in mean 24-h voiding frequency and nocturia in men, from 6.0 and 0.5 in the third decade to 8.5 and 1.6 in those aged > 70 years. Contrary to men, in women the mean 24-h frequency declined slightly in the older decades; it increased from 6.9 in the third to 8.2 in the sixth, declining to 7.8 in those aged > 70 years. Nocturia in women increased linearly, although slower than in men, from 0.7 in the third decade to 1.4 in those aged > 70 years. The mean volume/void decreased significantly in both genders, from 313 to 209 mL in men, and from 274 to 240 mL in women. The mean 24-h volume was 1718 and 1762 mL in men and women, respectively. For both genders there was a strong linear association between 24-h urine production and voided volumes. CONCLUSIONThe volume/void and maximum voided volume decreased significantly with age in both sexes, but more prominently in men. As a result, in men the frequency increased with age, probably reflecting subclinical changes associated with the development of prostatic enlargement. In contrast to men the frequency in women increased initially and decreased in the older groups. A higher 24-h urine production was associated with a higher mean volume/void.

No abstract

No abstract

The prevalence of nocturnal polyuria is overestimated. We suggest a new cutoff value for the nocturnal polyuria index, that is nocturnal polyuria exists when the nocturnal polyuria index exceeds 53%. The nocturia index is the best predictor of nocturia.

Recent progress in growth factor research has led to a reexamination of the involvement of neurotrophic factors outside their classical domain of the nervous system. These last few years have seen a substantial accumulation of data concerning Nerve Growth Factor (NGF)'s prevalence within the prostate. NGF and its receptors were reported from the normal prostatic tissue, benign hyperplasia and prostatic cancer. Divergent ideas about the biological role of this factor, its specific distribution pattern within the tissue and its implication in the progression of carcinogenesis have been proposed. Especially the role of NGF in the metastatic process bears direct clinical relevance for research in this area. Many questions remain to be solved like the one on the prevalence of other neurotrophic factors. It is now increasingly becoming clear that neurotrophic factors do play a role in normal physiology and pathology of prostatic cells, opening up new prospects for diagnosis and treatment.

The International Prostate Symptom Score nocturia score overestimated nocturia in most patients, as derived from a 7-day frequency-volume chart. When scoring International Prostate Symptom Score nocturia question 7, patients included a degree of bother. The correlation of question 7 with mean nocturia increased with frequency-volume chart duration until day 3.